Primary Percutaneous coronary intervention: The deception of delay

Journal of the American College of Cardiology

Volumn 61, Issue 16, 2013, Pages 1696-1697

  Grines, Cindy L ^a   Schreiber, Theodore ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

delay; door to balloon time; mortality; STEMI

Indexed keywords

FIBRINOLYTIC AGENT;

CEREBROVASCULAR ACCIDENT; DOOR TO BALLOON TIME; ELECTROCARDIOGRAPHY; EMERGENCY CARE; FIBRINOLYTIC THERAPY; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HEALTH EDUCATION; HEART MUSCLE REPERFUSION; HEART REINFARCTION; HUMAN; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NOTE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; SURVIVAL RATE; THERAPY DELAY; TIME TO TREATMENT;

EID: 84876254685     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.01.050     Document Type: Editorial

References (14)

1. Action Registry Data July 1, 2009 to June 30, 2010 http://www. cardiosource.org Accessed February 26, 2013
2. E.C. Keeley, J.A. Boura, C.L. Grines Primary angioplasty versus intravenous thrombolytic for acute myocardial infarction: a quantitative review of 23 randomised trials Lancet 361 2003 13 20
3. C.L. Grines, K.F. Browne, J. Marco A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction N Engl J Med 328 1993 673 679
4. C.P. Cannon, C.M. Gibson, C.T. Lambrew Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction JAMA 283 2000 2941 2947
5. R.L. McNamara, Y. Wang, J. Herrin Effect of door-to-balloon time on mortality in patients with ST-segment elevation myocardial infarction J Am Coll Cardiol 47 2006 2180 2186
6. C.J. Terkelsen, J.T. Sorensen, M. Maeng System delay and mortality among patients with STEMI treated with primary percutaneous coronary intervention JAMA 304 2010 763 771
7. M.P. Hudson, P.W. Armstrong, W.W. O'Neil Mortality implications of primary percutaneous coronary intervention treatment delays: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial Circ Cardiovasc Qual Outcomes 4 2011 183 192
8. E. Boersma, A.C. Maas, J.W. Deckers, M.L. Simoons Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour Lancet 348 1996 771 775
9. B.J. Gersh, G.W. Stone, H. White, D.R. Holmes Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future? JAMA 293 2005 979 986
10. A. Flynn, M. Moscucci, D. Share Trends in door-to-balloon time and mortality in patients with ST-elevation infarction undergoing primary percutaneous coronary intervention Arch Intern Med 170 2010 1842 1849
11. B.R. Brodie, C. Hansen, T.D. Stuckey Door-to-balloon time with primary percutaneous coronary intervention for acute myocardial infarction impacts late cardiac mortality in high-risk patients and patients presenting early after the onset of symptoms J Am Coll Cardiol 47 2006 289 295
12. J.C. Blankenship, K.A. Skelding, T.D. Scott Predictors of reperfusion delay in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention from the HORIZONS-AMI trial Am J Cardiol 106 2010 1527 1533
13. R.V. Swaminathan, T.Y. Wang, L.A. Kaltenbach Nonsystem reasons for delay in door-to-balloon time and associated in-hospital mortality: a report from the National Cardiovascular Data Registry J Am Coll Cardiol 61 2013 1688 1695
14. K.A. Eagle, B.K. Nallamothu, R.H. Mehta Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go Eur Heart J 29 2008 609 617